Tetrapyrroles and derivatives
Abcam L-745870 trihydrochloride, brain penetrant D4 antagonist, 50MG
MW 436.21 g/mol, Purity >99%. Highly potent and selective D₄ antagonist (Ki values are 0.43, 2300 and 960 nM at D₄, D₃ and D₂, respectively). Brain permeable. Inhibits cell death and shows neuroprotective effects.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SB 216641 hydrochloride, h5-HT1B antagonist, 50MG
MW 523.03 g/mol, Purity >98%. Selective h5-HT₁B receptor antagonist. 25-fold selectivity over h5-HT₁D. Little or no affinity for a range of other receptor subtypes.
The product is subject to the following: Abcam Restricted Use Statement
Abcam PNU 120596, Positive allosteric modulator for alpha7 nicotinic acetylcholine receptors, 10MG
MW 311.72 Da, Purity >99%. Competitive, type II positive allosteric modulator for α7nAChR (EC₅₀ = 216 nM). Increases potency of nicotinic agonists. No effect on α4β2, α3β4 and α9α10 nAChRs. Active in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Abcam TC-2403 o x alate, alpha4beta2 nAChR selective agonist, 50MG
MW 252.27 g/mol, Purity >99%. High affinity α4β2 nAChR selective agonist (Ki = 26 nM). Selective for CNS nAChR over muscle, ganglionic or enteric ACh receptors (EC₅₀ = 732 nM in rat thalamic synaptosomes).
The product is subject to the following: Abcam Restricted Use Statement
Abcam Pancuronium dibromide, Competitive nicotinic acetylcholine receptor antagonist, 50MG
MW 732.7 Da. Competitive nicotinic acetylcholine receptor (nAChR) antagonist. Displaces acetylcholine (ab120469) from nAChRs (IC₅₀ = 5.5 nM). Neuromuscular blocker and muscle relaxant.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Flupirtine maleate, Neuronal potassium channel opener, 10MG
MW 420.4 Da, Purity >99%. Neuronal potassium channel opener. Activates Kv7.2 channels and potently activates the inwardly rectifying potassium current (KIR; EC₅₀ = 600 nM). Centrally acting, non-opiate analgesic. Neuroprotective and antiapoptotic agent. Also has muscle relaxant properties. Active in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SEN 12333, alpha7 nicotinic acetylcholine receptor (nAChR) agonist, 10MG
MW 339.4 Da, Purity >98%. Potent, selective α7 nicotinic acetylcholine receptor (nAChR) agonist. High affinity for rat α7 receptors (Ki = 260 nM). Full agonist in functional Ca²+ flux studies (EC₅₀ = 1.6 μM). Active in vivo and in vitro. Excellent brain penetration. Orally bioavailable.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Z-Prolyl-prolinal (Z-Pro-Pro-CHO), Prolyl endopeptidase inhibitor, 25MG
MW 330.4 Da, Purity >97%. Z-Prolyl-prolinal (Z-Pro-Pro-CHO), Prolyl endopeptidase inhibitor. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam AR 231453, GPR119 agonist, 5MG
MW 505.5 Da, Purity >99%. Potent, selective G-protein coupled receptor 119 (GPR119) agonist (EC₅₀ = 0.68 nM). Enhances glucose-induced insulin release. Antidiabetic activity. Orally active in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Abcam AR 231453, GPR119 agonist, 25MG
MW 505.5 Da, Purity >99%. Potent, selective G-protein coupled receptor 119 (GPR119) agonist (EC₅₀ = 0.68 nM). Enhances glucose-induced insulin release. Antidiabetic activity. Orally active in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Abcam ENMD-1068, protease-activated receptor 2 (PAR2) anatagonist, 25MG
MW 283.41 Da, Purity >99%. Selective protease-activated receptor 2 (PAR2) antagonist (IC₅₀ = 1.2 mM). Anti-inflamatory agent. Active in vivo and in vitro.
The product is subject to the following: Abcam Restricted Use Statement
Abcam ENMD-1068, protease-activated receptor 2 (PAR2) anatagonist, 5MG
MW 283.41 Da, Purity >99%. Selective protease-activated receptor 2 (PAR2) antagonist (IC₅₀ = 1.2 mM). Anti-inflamatory agent. Active in vivo and in vitro.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Genipin, Cell-permeable uncoupling protein 2 inhibitor, 25MG
MW 226.23 g/mol, Purity >99%. Cell-permeable uncoupling protein 2 (UCP2) inhibitor. Anti-inflammatory, anti-angiogenic and pro-apototic effects. Acts as a protein cross-linker.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Rhodadyn™ B10, Negative control for Rhodadyn™ C10, 5MG
MW 322.44 g/mol, Purity >98%. Negative control for Rhodadyn™ C10 (ab120795). Demonstrates no significant inhibition of dynamin I or dynamin II in vitro GTPase activity at concentrations up to 300 μM and has no effect on clathrin-mediated endocytosis of transferrin when applied for 30 minutes to U2OS cells in culture. Robertson J et al. The rhodadyn™ a new class of small molecule inhibitors of dynamin GTPase. ACS Med. Chem (2012).
The product is subject to the following: Abcam Restricted Use Statement
Abcam (±)-SKF38393 hydrochloride, D1-like dopamine receptor agonist, 100MG
MW 291.77 Da, Purity >98%. D1-like dopamine receptor agonist. pKi values are 9 (D1), 6.8 (D2), 5.3 (D3), 6.0 (D4) and 9.3 (D5). Ki values are 151 and 2364 nM for D1-like and D2-like dopamine receptors, respectively. Centrally active upon systemic administration.
The product is subject to the following: Abcam Restricted Use Statement